利用患者来源的肺癌细胞系阐明肿瘤内异质性

Intratumoral heterogeneity has been reported to be associated with treatment resistance in various cancers, including lung cancer. Elucidating intratumoral heterogeneity is a critical issue that must be addressed to improve patient prognosis. Previous studies on intratumoral heterogeneity have primarily focused on collecting and analyzing patient-derived cancer cells, classifying them into subclones with distinct characteristics, and conducting comparative analyses. In contrast, few studies have focused on the early phase of intratumoral heterogeneity. We established a patient-derived cancer cell line (KTOR83) using pleural effusion collected from a lung cancer patient harboring a BRAF gene mutation. From KTOR83, we generated single-cell-derived clones and established five subclones (clones A, B, C, D, and E). In drug sensitivity assays using the BRAF inhibitor dabrafenib, clones A and B exhibited resistance, whereas clones C, D, and E were sensitive. In cell migration assays, clones D and E demonstrated high migratory capacity. In xenograft models, clones A, B, and C showed strong tumorigenic potential, while clones D and E exhibited low tumor-forming ability. Furthermore, flow cytometric analysis revealed that in clone C, the expression pattern of the cell surface marker EpCAM shifted from a unimodal to a bimodal distribution before and after dabrafenib exposure. To investigate whether this bimodal expression of EpCAM corresponds to two phenotypically distinct subclones, we plan to isolate EpCAM-high and EpCAM-low populations using flow cytometry and compare their phenotypic characteristics. Through cloning of patient-derived cancer cells, we confirmed the presence of subclones with distinct phenotypes. Moreover, in one of these clones, exposure to an anticancer drug induced a shift to bimodal expression of a cell surface marker, capturing an early event of intratumoral heterogeneity in which a single cell differentiates into phenotypically distinct populations. This study presents a novel approach to capturing the early phase of intratumoral heterogeneity and provides new insights into the mechanisms underlying tumor progression.